BridgeBio Pharma, Inc.
Congressional Trades
Whale Activity
- Increased187
- New60
- Held60
- Decreased144
- Closed60
- No prior filing20
| Filer | Shares | Value | Change |
|---|---|---|---|
| Janus Henderson Group Ltd. | 14.6M | $957.7M | — |
| FARALLON CAPITAL MANAGEMENT, L.L.C. | 14.2M | $937.5M | increased |
| BlackRock, Inc. | 10.4M | $683.6M | increased |
| VIKING GLOBAL INVESTORS LP | 9.8M | $644.3M | decreased |
| WELLINGTON MANAGEMENT GROUP LLP | 9.5M | $622.4M | increased |
| Kohlberg Kravis Roberts & Co. L.P. | 8.3M | $543.6M | decreased |
| VANGUARD CAPITAL MANAGEMENT LLC | 7.9M | $520.7M | increased |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 7.5M | $492.5M | decreased |
| STATE STREET CORP | 5.0M | $327.5M | increased |
| Invesco Ltd. | 4.3M | $284.1M | increased |
| JPMORGAN CHASE & CO | 4.0M | $264.5M | increased |
| FRANKLIN TEMPLETON INC | 3.3M | $255.4M | increased |
Every 13F filer's complete reported book, every quarter since 2013-06-30. 13F itself excludes short positions, cash and most options.
Insider Trading
Recent Insider Transactions
| Insider | Type | Shares | Price | Value | Date | |
|---|---|---|---|---|---|---|
| Kumar NeilChief Executive Officer · Director | Sale | −8,500 | $78.35 | $666K | Nov 19, 2026 | Form 4 ↗ |
| Kumar NeilChief Executive Officer · Director | Sale | −1,500 | $79.29 | $119K | Nov 19, 2026 | Form 4 ↗ |
| Kumar NeilChief Executive Officer · Director | Sale | −8,723 | $77.83 | $679K | Nov 18, 2026 | Form 4 ↗ |
| Kumar NeilChief Executive Officer · Director | Sale | −4,490 | $76.99 | $346K | Nov 18, 2026 | Form 4 ↗ |
| Kumar NeilChief Executive Officer · Director | Sale | −30.5K | $77.83 | $2.4M | Nov 18, 2026 | Form 4 ↗ |
| Kumar NeilChief Executive Officer · Director | Sale | −1,277 | $76.99 | $98K | Nov 18, 2026 | Form 4 ↗ |
| Apuli MaricelChief Accounting Officer | Sale | −2,000 | $72.85 | $146K | Oct 30, 2026 | Form 4 ↗ |
| Kumar NeilChief Executive Officer · Director | Sale | −1,279 | $69.57 | $89K | Sep 17, 2026 | Form 4 ↗ |
| Kumar NeilChief Executive Officer · Director | Sale | −8,721 | $69.01 | $602K | Sep 17, 2026 | Form 4 ↗ |
| Kumar NeilChief Executive Officer · Director | Sale | −100 | $85.65 | $9K | Aug 19, 2026 | Form 4 ↗ |
| Kumar NeilChief Executive Officer · Director | Sale | −1,800 | $84.69 | $152K | Aug 19, 2026 | Form 4 ↗ |
| Kumar NeilChief Executive Officer · Director | Sale | −8,100 | $83.86 | $679K | Aug 19, 2026 | Form 4 ↗ |
| Kumar NeilChief Executive Officer · Director | Sale | −1,199 | $83.77 | $100K | Aug 18, 2026 | Form 4 ↗ |
| Kumar NeilChief Executive Officer · Director | Sale | −14.6K | $82.99 | $1.2M | Aug 18, 2026 | Form 4 ↗ |
| Kumar NeilChief Executive Officer · Director | Sale | −17.3K | $82.21 | $1.4M | Aug 18, 2026 | Form 4 ↗ |
| Kumar NeilChief Executive Officer · Director | Sale | −1,900 | $81.15 | $154K | Aug 18, 2026 | Form 4 ↗ |
| Trimarchi ThomasPresident and CFO | Tax withholding | −22.8K | $79.86 | $1.8M | Aug 16, 2026 | Form 4 ↗ |
| Kumar NeilChief Executive Officer · Director | Tax withholding | −36.2K | $79.86 | $2.9M | Aug 16, 2026 | Form 4 ↗ |
| Kumar NeilChief Executive Officer · Director | Option exercise | +6,520 | — | — | Aug 16, 2026 | Form 4 ↗ |
| Kumar NeilChief Executive Officer · Director | Option exercise | +11.6K | — | — | Aug 16, 2026 | Form 4 ↗ |
Fund Holders
| Fund | Shares | Value | % of fund | As of |
|---|---|---|---|---|
| VANGUARD TOTAL STOCK MARKET INDEX FUND VANGUARD INDEX FUNDS | 5.6M | $417.1M | 0.02% | Jun 30, 2026 |
| VANGUARD SMALL-CAP INDEX FUND VANGUARD INDEX FUNDS | 4.0M | $300.9M | 0.16% | Jun 30, 2026 |
| VANGUARD HEALTH CARE FUND VANGUARD SPECIALIZED FUNDS | 3.2M | $253.3M | 0.66% | Jul 31, 2026 |
| VANGUARD SMALL-CAP GROWTH INDEX FUND VANGUARD INDEX FUNDS | 2.3M | $173.6M | 0.37% | Jun 30, 2026 |
| VANGUARD EXTENDED MARKET INDEX FUND VANGUARD INDEX FUNDS | 2.0M | $147.1M | 0.15% | Jun 30, 2026 |
| Janus Henderson Enterprise Fund Janus Investment Fund | 1.9M | $142.2M | 0.64% | Jun 30, 2026 |
| VANGUARD EXPLORER FUND | 1.7M | $138.2M | 0.62% | Jul 31, 2026 |
| Janus Henderson Global Life Sciences Fund Janus Investment Fund | 1.6M | $118.5M | 2.04% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund Fidelity Salem Street Trust | 1.6M | $111.5M | 0.34% | Apr 30, 2026 |
| State Street(R) SPDR(R) S&P(R) Biotech ETF SPDR SERIES TRUST | 1.5M | $110.0M | 1.02% | Jun 30, 2026 |
Mutual funds and ETFs whose N-PORT filings list BBIO's shares (CUSIP 10806X102), each fund at its latest report since Apr 21, 2026, largest positions first. Bonds, options and short positions are left out.
Activist & Passive Stakes
- Linn, Michael G.SCHEDULE 13G/A · passive (13G) · 14.2M shares7.3%
Nov 12, 2026 · ↗ - Kim, David T.SCHEDULE 13G/A · passive (13G) · 14.2M shares7.3%
Nov 12, 2026 · ↗ - Husen, Avner A.SCHEDULE 13G/A · passive (13G) · 14.2M shares7.3%
Nov 12, 2026 · ↗ - Giauque, NicolasSCHEDULE 13G/A · passive (13G) · 14.2M shares7.3%
Nov 12, 2026 · ↗ - Gehani, Varun N.SCHEDULE 13G/A · passive (13G) · 14.2M shares7.3%
Nov 12, 2026 · ↗ - Dunn Hannah E.SCHEDULE 13G/A · passive (13G) · 14.2M shares7.3%
Nov 12, 2026 · ↗ - Dreyfuss, Philip D.SCHEDULE 13G/A · passive (13G) · 14.2M shares7.3%
Nov 12, 2026 · ↗ - Dapice Joshua J.SCHEDULE 13G/A · passive (13G) · 14.2M shares7.3%
Nov 12, 2026 · ↗ - Wehrly, Mark C.SCHEDULE 13G/A · passive (13G) · 14.2M shares7.3%
Nov 12, 2026 · ↗ - Warren, John R.SCHEDULE 13G/A · passive (13G) · 14.2M shares7.3%
Nov 12, 2026 · ↗
Corporate Lobbying
No lobbying filings found naming BridgeBio Pharma, Inc. as the client.
Government Contracts
No federal contract awards found for BridgeBio Pharma, Inc..
U.S. Patents
No USPTO patent applications found for BridgeBio Pharma, Inc..
Annual Financials
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $502.1M | $221.9M | $9.3M | $77.6M | $69.7M |
| Operating income | -$523.4M | -$593.0M | -$607.4M | -$512.2M | -$576.6M |
| Diluted EPS | -$3.78 | -$2.88 | -$3.95 | -$3.26 | -$3.90 |
| Operating cash flow | -$445.9M | -$520.7M | -$527.7M | -$419.5M | -$497.9M |
| Cash and equivalents | $570.1M | $681.1M | $375.9M | $376.7M | $393.8M |
| Total assets | $936.0M | $919.3M | $546.4M | $623.0M | $1.01B |
| Total liabilities | $3.01B | $2.38B | $1.89B | $1.87B | $1.88B |
| Shareholders' equity | -$2.09B | -$1.47B | -$1.35B | -$1.25B | -$870.4M |
As BridgeBio Pharma, Inc. tagged them in its 10-K filings: totals for the year on the income and cash-flow lines, values at the year's end on the balance-sheet lines. Latest 10-K, filed Feb 24, 2026 ↗
Stock Splits
No stock splits in BBIO's price history.
Material Events (8-K)
- 8-K · Items 2.02, 9.01Results of operationsOct 29, 2026
EDGAR ↗ - 8-K · Items 8.01, 9.01Other eventsOct 13, 2026
EDGAR ↗ - 8-K · Items 8.01, 9.01Other eventsAug 31, 2026
EDGAR ↗ - 8-K · Items 1.01, 8.01, 9.01Material agreement · Other eventsAug 17, 2026
EDGAR ↗ - 8-K · Items 2.02, 9.01Results of operationsAug 10, 2026
EDGAR ↗ - 8-K · Items 8.01, 9.01Other eventsJul 22, 2026
EDGAR ↗ - 8-K · Items 1.01, 3.02, 3.03, 5.03, 7.01, 9.01Material agreement · Unregistered sale of equity · Modification of rightsJul 2, 2026
EDGAR ↗ - 8-K · Items 5.02, 5.07, 9.01Officer / director change · Shareholder voteJun 26, 2026
EDGAR ↗ - 8-K · Items 8.01, 9.01Other eventsMay 27, 2026
EDGAR ↗ - 8-K · Items 8.01, 9.01Other eventsMay 13, 2026
EDGAR ↗

